비전이성 전립선암(nmPC) : 시장 인사이트, 역학 및 시장 예측(2036년)

Non-metastatic Prostate Cancer (nmPC) Insights and Trends

• According to DelveInsight's analysis, nmPC market size was found to be ~USD 3,600 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• Prostate cancer happens when abnormal cells form and grow in the prostate gland. Unlike benign (or non-cancerous) growths, these growths are cancerous (malignant). Prostate cancer can be life-threatening if it becomes "metastatic" and spreads beyond the prostate. Early stages of prostate cancer rely on testosterone to grow; sometimes, lowering testosterone can control growth.
• Castration-resistant prostate cancer (CRPC) is a form of advanced prostate cancer. If prostate cancer is diagnosed as CRPC, it can grow or spread even with low testosterone levels, and with non-metastatic CRPC (nmCRPC), the cancer no longer responds to hormone treatment. It shows signs of growth, like a rising PSA (prostate-specific antigen) level, but it is only found in the prostate and has not spread.
• Often, there are no symptoms for patients with nmCRPC. Most men cannot tell if the cancer is growing unless the doctor notices a rise in the PSA level. Changes are tracked with blood tests, physical exams, and scans, such as CT, bone, and PET scans.
• The current nmPC treatment landscape includes only three drugs have been approved by the US FDA for nmCRPC, including Enzalutamide (XTANDI, Pfizer and Astellas), Apalutamide (ERLEADA, Janssen Biotech), and Darolutamide (NUBEQA, Bayer).
• Whereas the emerging nmPC pipeline remains relatively limited, a small number of late- and mid-stage assets such as Relugolix (ORGOVYX), CAN-2409, KPG-121, and OVM-200 are being evaluated.

Non-metastatic Prostate Cancer Market Size and Forecast in the 7MM

• 2025 nmPC Market Size: ~USD 3,600 million
• 2036 Projected nmPC Market Size: USD 5,500million
• nmPC Growth Rate (2026-2036): 4% CAGR

DelveInsight's 'Non-metastatic Prostate Cancer (nmPC) - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the non-metastatic prostate cancer, historical and forecasted epidemiology, as well as the Non-metastatic Prostate Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Non-metastatic Prostate Cancer market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, Non-metastatic Prostate Cancer patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Non-metastatic Prostate Cancer and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Non-metastatic Prostate Cancer Market

Rising Disease Detection and Screening

Widespread use of PSA testing and improved diagnostic imaging increases early diagnosis of non metastatic prostate cancer.

Expansion of Targeted Therapies

Adoption of next generation androgen receptor inhibitors (e.g., apalutamide, enzalutamide, darolutamide) with proven efficacy in delaying progression fuels market uptake.

Research and Pipeline Innovation

Ongoing development of novel agents and combination strategies continues to expand therapeutic options and attract investment.

Non-metastatic Prostate Cancer Understanding and Treatment Algorithm

Non-metastatic Prostate Cancer Overview and Diagnosis

Non-metastatic Prostate Cancer refers to prostate cancer that is confined to the prostate gland or surrounding local tissues without evidence of distant metastasis. The condition is often asymptomatic in its early stages and is frequently identified through elevated prostate-specific antigen (PSA) levels or abnormalities detected during a digital rectal examination (DRE). Diagnosis is confirmed via prostate biopsy, which determines tumor grade and aggressiveness, while imaging modalities such as multiparametric MRI, CT scans, or bone scans are used to assess local spread and exclude distant disease. Risk stratification based on PSA levels, Gleason score, and tumor staging plays a critical role in guiding management. Early diagnosis is essential, as non-metastatic prostate cancer is generally associated with favorable prognosis and a wide range of effective treatment options, including active surveillance, surgery, and radiation therapy.

Non-metastatic Prostate Cancer Diagnosis

Diagnosis of Non-metastatic Prostate Cancer is based on a combination of clinical evaluation and diagnostic testing. It is typically suspected in men with elevated prostate-specific antigen (PSA) levels or abnormal findings on digital rectal examination (DRE). Confirmation is achieved through a prostate biopsy, which determines tumor grade and aggressiveness. Imaging techniques such as multiparametric MRI are used to assess local tumor extent, while CT scans or bone scans help rule out distant metastasis, ensuring accurate staging and appropriate treatment planning.

Non-metastatic Prostate Cancer Treatment

Treatment of Non-metastatic Prostate Cancer depends on disease risk, patient age, and overall health, with the goal of controlling cancer while preserving quality of life. Common approaches include active surveillance for low-risk cases and definitive treatments such as radical prostatectomy or radiation therapy for higher-risk disease. In selected patients, androgen deprivation therapy (ADT) may be used, often in combination with radiation. Additional therapeutic options include focal therapies (such as cryotherapy or high-intensity focused ultrasound) for localized lesions, and in certain high-risk non-metastatic settings, next-generation hormonal therapies may be considered. Overall, a range of treatment modalities allows for personalized management, with most patients achieving a favorable prognosis when treated appropriately.

Non-metastatic Prostate Cancer Unmet Needs

The section "unmet needs of Non-metastatic Prostate Cancer" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Lack of curative therapy

2. Need for early diagnosis

3. Lack of consensus on genetic testing and treatment

4. Cross-resistance between available androgen receptor pathway inhibitors, and others.....

Comprehensive unmet needs insights in Non-metastatic Prostate Cancer and their strategic implications are provided in the full report.

Non-metastatic Prostate Cancer Epidemiology

Key Findings from Non-metastatic Prostate Cancer Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, the total market size of Non-metastatic Prostate Cancer in the US were approximately 2,500 in 2025.
• Spain accounted for the least market size among the 7MM countries which was ~USD 110 million in 2025.
• The market for the non-metastatic prostate cancer accounts for around 25% of the 7MM's overall market size of prostate cancer in 2025.
• Approximately one in nine men in the US is diagnosed with this disease at some point. As per the American Cancer Society, 2019, prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer.

Non-metastatic Prostate Cancer Drug Chapters & Competitive Analysis

The Non-metastatic Prostate Cancer drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the Non-metastatic Prostate Cancers treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Non-metastatic Prostate Cancer therapeutics market.

Approved Therapies for Non-metastatic Prostate Cancer

Apalutamide (ERLEADA): Janssen Pharmaceutical

Apalutamide (ERLEADA) is a small molecule androgen receptor antagonist which binds to the intracellular receptor and prevents its translocation to the nucleus and subsequent DNA binding, thereby blocking its activity. Apalutamide is a third generation, oral nonsteroidal antiandrogen used to treat non-metastatic castration-resistant prostate cancer. Therapy with apalutamide lowers residual testosterone levels after surgical castration in men with prostate cancer and has been shown to prolong metastasis free survival in men with castration-resistant prostate cancer with rising levels of prostate-associated antigen (PSA) without measurable metastatic disease.

Enzalutamide (XTANDI): Astellas Pharma/Pfizer

XTANDI (enzalutamide) is an orally bioavailable, organic, non-steroidal small molecule targeting the AR with potential antineoplastic activity. Through a mechanism different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum PSA level. AR overexpression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.

In November 2023, XTANDI Approved by US FDA for Non-metastatic Castration-Sensitive Prostate Cancer, First ARSI Option With or Without GnRH Therapy.

Non-metastatic Prostate Cancer Pipeline Analysis

Relugolix (ORGOVYX): Sumitomo Pharma/Pfizer

ORGOVYX (relugolix) is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the FDA for treating adult patients with advanced prostate cancer. As a GnRH antagonist, ORGOVYX blocks the GnRH receptor and reduces the production of testicular testosterone, a hormone known to stimulate the growth of prostate cancer. Relugolix is a non-peptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors, thereby reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and, consequently, testosterone.

Eligible patients in clinical trial were treated with leuprolide acetate or degarelix with abiraterone or apalutamide prior to baseline, at which time they were transitioned to relugolix. Assessments included reporting of adverse events, clinical laboratory tests, vital sign measurements, electrocardiogram (ECG) parameters, and testosterone serum concentrations. The drug ORGOVYX is presently undergoing evaluation in a Phase I clinical trial to assess its safety and tolerability in patients.

CAN-2409: Candel Therapeutics

CAN-2409, Candel's most advanced viral immunotherapy candidate, is a replication-defective adenovirus that delivers the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells. HSV-tk is an enzyme that locally converts orally administered Val acyclovir into a toxic metabolite that kills nearby cancer cells. The intra-tumoral administration results in the release of tumor-specific neoantigens in the microenvironment. At the same time, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment, which is designed to create the optimal conditions to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor.

The drug CAN-2409 is presently undergoing evaluation in a Phase III clinical trial to assess its safety and tolerability in patients.

Non-metastatic Prostate Cancer (nmPC) Key Players, Market Leaders and Emerging Companies

• Janssen Pharmaceutical
• Astellas Pharma/Pfizer
• Bayer
• Myovant
• Sumitomo Pharma
• Takeda
• Accord
• Candel Therapeutics
• Kangpu Biopharmaceuticals
• Oxford Vacmedix, and others

Non-metastatic Prostate Cancer (nmPC) Drug Updates

• In March 2026, Candel Therapeutics to present extended follow-up data from Phase III CAN-2409 trial in localized prostate cancer at AUA 2026 annual meeting.
• In October 2025, Astellas to showcase innovative portfolio and pipeline developments at ESMO 2025.
• In September 2025 Candel Therapeutics showcases Phase III CAN-2409 clinical trial in localized prostate cancer at ASTRO 2025.
• In May 2025, FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation to Candel Therapeutics' CAN-2409 for prostate cancer treatment.

Drug Class Insights

Non-metastatic Prostate Cancer (nmPC) Market Outlook

The Prostate Cancer market is undergoing a notable transformation, moving beyond traditional reliance on androgen deprivation therapy (ADT) and chemotherapy toward more targeted and precision-driven treatment approaches. The expanding use of next-generation androgen receptor inhibitors such as Enzalutamide and Apalutamide, along with PARP inhibitors and radioligand therapies, reflects a shift toward mechanism-based, disease-modifying strategies. These advancements are strengthening clinical confidence in targeted interventions and reshaping the competitive landscape by broadening therapeutic options across both non-metastatic and metastatic settings.

With continued innovation in areas such as DNA damage repair-targeted therapies, radiopharmaceuticals, and combination regimens, the prostate cancer treatment paradigm is evolving in line with other oncology markets where early targeted successes drive further pipeline expansion. The United States remains the largest market, supported by high disease prevalence, widespread PSA screening, early adoption of advanced therapies, and strong healthcare infrastructure, compared to Europe and Japan.

Overall, the introduction of novel targeted agents, improved diagnostic and imaging techniques, and increasing awareness of early-stage disease management are expected to drive steady growth in the 7MM prostate cancer market through 2036, with significant commercial opportunities for both established therapies and emerging pipeline assets.

• The Non-metastatic Prostate Cancer market is evolving as treatment focus shifts from conventional androgen deprivation therapy to next-generation androgen receptor inhibitors and targeted therapies, with agents such as Apalutamide, Enzalutamide, and Darolutamide driving adoption due to their proven efficacy in delaying metastasis, favorable safety profiles, and increasing integration into earlier stages of disease management.
• Regional market dynamics show the United States leading in revenue, driven by high diagnosis rates, widespread PSA screening, early adoption of next-generation androgen receptor inhibitors, and strong reimbursement frameworks. In contrast, Japan and Europe demonstrate steady growth, supported by improving diagnosis, gradual uptake of advanced therapies, and expanding access to innovative treatments within structured healthcare systems.
• In 2036, among all the therapies for nmPC, XTANDI (enzalutamide) is expected to remain the top revenue-generating therapy in the non-metastatic prostate cancer market over the forecast period due to its market leadership and expanded indications.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Non-metastatic Prostate Cancer (2022-2036 Forecast)

The Non-metastatic Prostate Cancer market comprises androgen deprivation therapies, next-generation androgen receptor inhibitors, and emerging targeted agents, alongside surgical, radiation, and supportive approaches, each addressing key biological drivers such as androgen signaling, tumor progression, and resistance mechanisms underlying disease development and progression.

• Oncolytic gene therapy: CAN-2409 is an investigational adenoviral vector-based gene therapy designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene directly into tumor cells, enabling targeted cell death upon administration of a prodrug. It stimulates both direct tumor cytotoxicity and systemic anti-tumor immune responses, highlighting the potential of gene-mediated immunotherapy in prostate cancer.
• Androgen receptor inhibitors: Apalutamide (ERLEADA) is a next-generation androgen receptor inhibitor that blocks androgen receptor signaling, a key driver of prostate cancer progression. It has demonstrated efficacy in delaying metastasis and disease progression in non-metastatic castration-resistant prostate cancer, supporting its role as a standard of care in earlier disease settings.
• Androgen receptor inhibitors: Enzalutamide (XTANDI) is a potent androgen receptor signaling inhibitor that prevents androgen receptor nuclear translocation and DNA binding. It has shown significant benefit in improving metastasis-free survival and delaying disease progression, reinforcing the importance of targeting androgen signaling pathways in prostate cancer management

Non-metastatic Prostate Cancer Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the Non-metastatic Prostate Cancer market's uptake by drugs, patient uptake by therapy, and sales of each drug.

The uptake of therapies in Non-metastatic Prostate Cancer (nmPC) is expected to vary across next-generation androgen receptor inhibitors and conventional androgen deprivation therapies. Established targeted therapies such as Apalutamide (ERLEADA) and Enzalutamide (XTANDI) demonstrate strong and sustained uptake, while Darolutamide (NUBEQA) is anticipated to show steady and increasing adoption, supported by its favorable safety profile and lower central nervous system-related adverse effects. Their use is primarily driven by their proven ability to delay metastasis and improve metastasis-free survival, along with the limitations of conventional ADT alone in controlling disease progression.

In comparison, these next-generation androgen receptor inhibitors are expected to maintain consistent and competitive uptake as long-term efficacy and safety data continue to mature, and as they become more firmly embedded in treatment guidelines. Their adoption is further supported by increasing physician confidence, expanding clinical evidence, and a growing emphasis on early intervention to delay disease progression, reinforcing their central role in the evolving nmPC treatment landscape.

Market Access and Reimbursement of nmPC

• The United States

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Non-metastatic Prostate Cancer Therapies Price Scenario & Trends

Pricing and analogue assessment of Non-metastatic Prostate Cancer therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

• Pricing of Non-metastatic Prostate Cancer Approved Drugs

Apalutamide (ERLEADA) is administered at a recommended dose of 240 mg orally once daily. The list price for a supply of approximately 30 days (120 tablets of 60 mg) is around USD 15,356.89, translating to an estimated annual therapy cost of approximately USD 184,000-185,000, depending on treatment duration and adherence.

Further details are provided in the final report....

Industry Experts and Physician Views for Non-metastatic Prostate Cancer

To keep up with nmPC market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the nmPC emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in nmPC, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the University of North Carolina at Chapel Hill, Berlin Institute of Health at Charite, and the University of Nottingham, etc. were contacted. Their opinion helps understand and validate current and emerging nmPC therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in nmPC.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Non-metastatic Prostate Cancer (nmPC), strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of nmPC, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM non-metastatic Prostate Cancer (nmPC) market.

Report Insights

• nmPC Patient Population Forecast
• nmPC Therapeutics Market Size
• nmPC Pipeline Analysis
• nmPC Market Size and Trends
• nmPC Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year forecast
• nmPC Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• nmPC Treatment Addressable Market (TAM)
• nmPC Competitive Landscape
• nmPC Major Companies Insights
• nmPC Price Trends and Analogue Assessment
• nmPC Therapies Drug Adoption/Uptake
• nmPC Therapies Peak Patient Share analysis

Report Assessment

• nmPC Current Treatment Practices
• nmPC Unmet Needs
• nmPC Clinical Development Analysis
• nmPC Emerging Drugs Product Profiles
• nmPC Market Attractiveness
• nmPC Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the nmPC market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of nmPC?
• What are the disease risks, burdens, and unmet needs of nmPC? What will be the growth opportunities across the 7MM concerning the patient population with nmPC?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of nmPC? What are the current guidelines for treating nmPC in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the nmPC market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Forecast Methodology

6. nmPC Market Overview at a Glance

• 6.1. Clinical Landscape Analysis (By Phase, Molecule Type, and RoA)
• 6.2. Market Share (%) Distribution of nmPC By Therapies in the 7MM, in 2025
• 6.3. Market Share (%) Distribution of nmPC By Therapies in the 7MM, in 2036

7. Disease Background and Overview of Non-Metastatic Prostate Cancer (nmPC)

• 7.1. Introduction
• 7.2. Types
• 7.3. Symptoms
• 7.4. Causes
• 7.5. Pathophysiology
• 7.6. Diagnosis
• 7.7. Treatment

8. Treatment Guidelines of Non-Metastatic Prostate Cancer (nmPC)

• 8.1. American College of Rheumatology
• 8.2. EULAR/Pres Recommendations for the Diagnosis and Management of Still's Disease
• 8.3. Japan College of Rheumatology Clinical Practice Guidelines

9. Epidemiology and Patient Population of Non-Metastatic Prostate Cancer (nmPC)

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Diagnosed Prevalent Cases of nmPC in the 7MM
• 9.4. The United States
  • 9.4.1. Total Diagnosed Prevalent Cases of nmPC in the United States
  • 9.4.2. Age-specific Diagnosed Prevalent Cases of nmPC in the United States
  • 9.4.3. Stage-specific Diagnosed Prevalent Cases of nmPC in the United States
  • 9.4.4. Total Line-wise Treated Cases of nmPC in the United States
• 9.5. EU4 and the UK
  • 9.5.1. Total Diagnosed Prevalent Cases of nmPC in EU4 and the UK
  • 9.5.2. Age-specific Diagnosed Prevalent Cases of nmPC in EU4 and the UK
  • 9.5.3. Stage-specific Diagnosed Prevalent Cases of nmPC in EU4 and the UK
  • 9.5.4. Total Line-wise Treated Cases of nmPC in EU4 and the UK
• 9.6. Japan
  • 9.6.1. Total Diagnosed Prevalent Cases of nmPC in Japan
  • 9.6.2. Age-specific Diagnosed Prevalent Cases of nmPC in Japan
  • 9.6.3. Stage-specific Diagnosed Prevalent Cases of nmPC in Japan
  • 9.6.4. Total Line-wise Treated Cases of nmPC in Japan

10. Patient Journey of Non-Metastatic Prostate Cancer (nmPC)

11. Marketed Therapies

• 11.1. Marketed Competitive Landscape of Non-Metastatic Prostate Cancer (nmPC)
• 11.2. Apalutamide (ERLEADA): Janssen Pharmaceutical
  • 11.2.1. Drug Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Summary of Pivotal Trials
  • 11.2.5. Clinical Development
    • 11.2.5.1. Clinical Trial Information
  • 11.2.6. Analyst Views
• 11.3. Enzalutamide (XTANDI): Astellas Pharma/Pfizer
  • 11.3.1. Drug Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Developmental Activities
  • 11.3.4. Summary of Pivotal Trials
  • 11.3.5. Clinical Development
    • 11.3.5.1. Clinical Trial Information
  • 11.3.6. Analyst Views
• 11.4. Darolutamide (NUBEQA): Bayer
  • 11.4.1. Drug Description
  • 11.4.2. Regulatory Milestones
  • 11.4.3. Other Developmental Activities
  • 11.4.4. Summary of Pivotal Trials
  • 11.4.5. Clinical Development
    • 11.4.5.1. Clinical Trial Information
  • 11.4.6. Analyst Views

12. Emerging Drugs

• 12.1. Emerging Competitive Landscape of Non-Metastatic Prostate Cancer (nmPC)
• 12.2. Relugolix (ORGOVYX): Myovant/Sumitomo Pharma/Takeda/Accord
  • 12.2.1. Drug Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
    • 12.2.3.1. Clinical Trials Information
  • 12.2.4. Analyst Views
• 12.3. CAN-2409: Candel Therapeutics
  • 12.3.1. Drug Description
  • 12.3.2. Other Developmental Activity
  • 12.3.3. Clinical Development
    • 12.3.3.1. Clinical Trials Information
  • 12.3.4. Analyst Views
• 12.4. KPG-121: Kangpu Biopharmaceuticals
  • 12.4.1. Drug Description
  • 12.4.2. Clinical Development
    • 12.4.2.1. Clinical Trial Information
  • 12.4.3. Safety and Efficacy
  • 12.4.4. Analyst Views

13. Non-Metastatic Prostate Cancer (nmPC): 7MM Analysis

• 13.1. Key Findings
• 13.2. Market Outlook of Non-Metastatic Prostate Cancer (nmPC)
• 13.3. Conjoint Analysis of Non-Metastatic Prostate Cancer (nmPC)
• 13.4. Key Market Forecast Assumptions
  • 13.3.1. Cost Assumptions
  • 13.3.2. . Pricing Trends
  • 13.3.3. Analogue Assessment
  • 13.3.4. Launch Year and Therapy Uptakes
• 13.5. Total Market Size of nmPC in the 7MM
• 13.6. Total Market Size of nmPC by Therapies in the 7MM
• 13.7. The United States
  • 13.7.1. Total Market Size of nmPC in the United States
  • 13.7.2. Total Market Size of nmPC by Therapies in the United States
• 13.8. EU4 and the UK
  • 13.8.1. Total Market Size of nmPC in EU4 and the UK
  • 13.8.2. Total Market Size of nmPC by Therapies in EU4 and the UK
• 13.9. Japan
  • 13.9.1. Total Market Size of nmPC in Japan
  • 13.9.2. Total Market Size of nmPC by Therapies in Japan

14. Unmet Needs of Non-Metastatic Prostate Cancer (nmPC)

15. SWOT Analysis of Non-Metastatic Prostate Cancer (nmPC)

16. KOL Views of Non-Metastatic Prostate Cancer (nmPC)

17. Market Access and Reimbursement of Non-Metastatic Prostate Cancer (nmPC)

• 17.1. The United States
• 17.2. EU4 and the UK
  • 17.2.1. Germany
  • 17.2.2. France
  • 17.2.3. Italy
  • 17.2.4. Spain
  • 17.2.5. United Kingdom
• 17.3. Japan
• 17.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
• 17.5. Market Access and Reimbursement of Non-Metastatic Prostate Cancer (nmPC) Therapies

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight